164 related articles for article (PubMed ID: 31798346)
1. Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment.
Gao Y; Dorn P; Liu S; Deng H; Hall SRR; Peng RW; Schmid RA; Marti TM
Cancer Cell Int; 2019; 19():317. PubMed ID: 31798346
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR).
Gao Y; Zens P; Su M; Gemperli CA; Yang H; Deng H; Yang Z; Xu D; Hall SRR; Berezowska S; Dorn P; Peng RW; Schmid RA; Wang W; Marti TM
J Exp Clin Cancer Res; 2021 Apr; 40(1):138. PubMed ID: 33874986
[TBL] [Abstract][Full Text] [Related]
3. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on
Mohiuddin M; Kasahara K
Cancer Genomics Proteomics; 2021; 18(4):579-590. PubMed ID: 34183390
[TBL] [Abstract][Full Text] [Related]
5. BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness.
Shen HT; Chien PJ; Chen SH; Sheu GT; Jan MS; Wang BY; Chang WW
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32726929
[TBL] [Abstract][Full Text] [Related]
6. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
[TBL] [Abstract][Full Text] [Related]
7. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis.
Zheng F; Xu R
Biomed Pharmacother; 2020 Apr; 124():109828. PubMed ID: 31986409
[TBL] [Abstract][Full Text] [Related]
8. Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells.
Shang B; Jia Y; Chen G; Wang Z
Respir Res; 2017 Apr; 18(1):56. PubMed ID: 28399858
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
Koba T; Minami S; Nishijima-Futami Y; Masuhiro K; Kimura H; Futami S; Yaga M; Mori M; Kagawa H; Uenami T; Kohmo S; Otsuka T; Yamamoto S; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):111-117. PubMed ID: 29728800
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed combination therapy in the treatment of non-small cell lung cancer.
Rosell R; Crinó L
Semin Oncol; 2002 Apr; 29(2 Suppl 5):23-9. PubMed ID: 12023789
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
12. [Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases].
Wang W; Shang L; Li X; Li J; Wen F; Liu J
Zhongguo Fei Ai Za Zhi; 2011 Jan; 14(1):54-7. PubMed ID: 21219833
[TBL] [Abstract][Full Text] [Related]
13. Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549.
Tièche CC; Gao Y; Bührer ED; Hobi N; Berezowska SA; Wyler K; Froment L; Weis S; Peng RW; Bruggmann R; Schär P; Amrein MA; Hall SRR; Dorn P; Kocher G; Riether C; Ochsenbein A; Schmid RA; Marti TM
Neoplasia; 2019 Feb; 21(2):185-196. PubMed ID: 30591423
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
Fukushima T; Wakatsuki Y; Kobayashi T; Sonehara K; Tateishi K; Yamamoto M; Masubuchi T; Yoshiike F; Hirai K; Hachiya T; Koizumi T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1043-1050. PubMed ID: 29644460
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
Hsu DS; Balakumaran BS; Acharya CR; Vlahovic V; Walters KS; Garman K; Anders C; Riedel RF; Lancaster J; Harpole D; Dressman HK; Nevins JR; Febbo PG; Potti A
J Clin Oncol; 2007 Oct; 25(28):4350-7. PubMed ID: 17906199
[TBL] [Abstract][Full Text] [Related]
18. Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries.
Grossi F; Bennouna J; Havel L; Hochmair M; Almodovar T
Curr Med Res Opin; 2016 Sep; 32(9):1577-84. PubMed ID: 27223813
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
